Provided is a pharmaceutical preparation composition comprising a polymerized camptothecin derivative which is obtained by bonding a camptothecin derivative to a polymer carrier, and has nanoparticle-forming properties of associating in an aqueous solution, the pharmaceutical preparation composition having enhanced preparation stability. Particularly, a pharmaceutical preparation maintaining nanoparticle-forming properties, which are an important factor, and having an excellent storage stability is provided.

Disclosed is a pharmaceutical preparation comprising a block copolymer in which a polyethylene glycol segment is linked to a polyglutamic acid segment containing a glutamic acid unit having a camptothecin derivative bonded thereto, the pharmaceutical preparation capable of forming associates in an aqueous solution. When the pharmaceutical preparation is made into an aqueous solution containing the camptothecin derivative at a concentration of 1 mg/mL, the pH of the aqueous solution is 2.4 to 7.0, and the change ratio of the associate-forming ability of the pharmaceutical preparation after storage at 40° C. for one week under light-blocked conditions is 50% or less.

Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.

Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.

Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.

Copolymers polymerized from at least one or more cinchona alkaloid containing compounds; and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Method of forming a copolymer-genetic component complex that includes a genetic component and a copolymer where the copolymer includes one or more cinchona alkaloid containing compounds and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Methods of delivering a genetic component to a cell.

Copolymers polymerized from at least one or more cinchona alkaloid containing compounds; and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Method of forming a copolymer-genetic component complex that includes a genetic component and a copolymer where the copolymer includes one or more cinchona alkaloid containing compounds and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Methods of delivering a genetic component to a cell.

The unique polymeric OGF and enkephalin peptide conjugates with large size polymer attached at the C-terminus through hydrolysable linkage enhancing therapeutic properties of OGF and enkephalin peptides.

An antibody-drug conjugate having a cyclic benzylidene acetal linker represented by formula (1) or formula (2), wherein Y is an antibody; D is a drug; R.sup.1 and R.sup.6 are each independently a hydrogen atom or a hydrocarbon group; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently an electron-withdrawing or electron-donating substituent or a hydrogen atom; s is 1 or 2, t is 0 or 1, and s+t is 1 or 2; w is an integer of 1 to 20; and Z.sup.1 and Z.sup.2 are each independently a selected divalent spacer:

##STR00001##

The instant invention provides RNA nanocubes, DNA nanocubes and R/DNA chimeric nanocubes comprising one or more functionalities. The multifunctional RNA nanocubes are suitable for therapeutic or diagnostic use in a number of diseases or disorders.

A lipid membrane structure encapsulating an siRNA inside thereof and containing a lipid compound of the formula (I) as a lipid component (R.sup.1 and R.sup.2 represent CH.sub.3—(CH.sub.2).sub.n—CH═CH—CH.sub.2—CH═CH—(CH.sub.2).sub.m—, n represents an integer of 3 to 5, m represents an integer of 6 to 10, p represents an integer of 2 to 7, and R.sup.3 and R.sup.4 represent a C.sub.1-4 alkyl group or a C.sub.2-4 alkenyl group.